Literature DB >> 10348950

The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: What's New? What's Different?

.   

Abstract

Hypertension remains a major cause of cardiovascular morbidity and mortality in the United States. Disturbing trends have been reported recently and include declining rates of successful blood pressure control and increasing rates of stroke, congestive heart failure, and hypertension-associated end-stage renal disease. Recent clinical trials have demonstrated the potential benefits of more aggressive blood pressure control using specific antihypertensive agents in patients with both diabetic and nondiabetic renal disease. Additional studies have demonstrated the benefit of treating isolated systolic hypertension in the elderly and the potential for lifestyle modification to lower blood pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure has been published recently and should serve as an important resource for busy practitioners caring for hypertensive patients. This article describes the significant additions and revisions that distinguish this Sixth Report from previous editions.

Entities:  

Year:  1998        PMID: 10348950     DOI: 10.1097/00045415-199809000-00009

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  2 in total

1.  Reducing Test Anxiety by Device-Guided Breathing: A Pilot Study.

Authors:  Zehava Ovadia-Blechman; Ricardo Tarrasch; Maria Velicki; Hila Chalutz Ben-Gal
Journal:  Front Psychol       Date:  2022-05-23

2.  Epidemiological characteristics of elevated blood pressure among middle and high school students aged 12-17 years: a cross-sectional study in Jiangsu Province, China, 2017-2018.

Authors:  Xiyan Zhang; Jie Yang; Yan Wang; Weina Liu; Wenyi Yang; Liuwei Gao; Rainer Schwertz; Andreas Welker; Fengyun Zhang; Yonglin Zhou
Journal:  BMJ Open       Date:  2019-08-24       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.